GILEAD SCIENCES, INC. - 02 Apr 2024 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: 10%+ Owner
Signature: Gilead Sciences, Inc. By: /s/ Andrew D. Dickson
Issuer symbol: XLO
Transactions as of: 02 Apr 2024
Net transactions value: +$3,319,064
Form type: 4
Filing time: 03 Apr 2024, 18:50:01 UTC
Previous filing: 03 Apr 2024
Next filing: 19 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XLO	Common Stock	Purchase	$368,790	+485,250	+7.1%	$0.7600	7,345,473	02 Apr 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XLO	Prefunded Warrants (right to buy)	Purchase	$2,950,274	+3,882,450		$0.7599	3,882,450	02 Apr 2024	Common Stock	3,882,450	$0.000100	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.

Content

The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.